Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lulizumab vs Tacrolimus in Renal Transplant
NCT04903054Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Modality
- Antibody Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lulizumab pegol in kidney transplantation, sponsored by National Institute of Allergy and Infectious Diseases. Planned start Jan 2022; status: withdrawn.
02
Drugs
lulizumab pegol
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT04903054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903054.